Last updated: February 19, 2026
Tagrisso (osimertinib) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. This analysis details its ongoing clinical trial development, current market position, and projected market trajectory.
What is the Current Status of Tagrisso's Clinical Development?
Tagrisso's clinical development pipeline is extensive, focusing on expanding its approved indications, assessing its efficacy in earlier lines of therapy, and evaluating its combination potential. The drug is currently being investigated across a spectrum of NSCLC patient populations and disease stages.
Key ongoing and recently completed trials include:
- Adjuvant and Neoadjuvant Settings:
- ADAURA: This Phase III trial demonstrated a significant improvement in invasive disease-free survival (IDFS) and distant-DFS in patients with Stage IB-IIIA EGFR-mutated NSCLC who received adjuvant Tagrisso following complete tumor resection. The primary results, presented in 2020, showed a 51% reduction in the risk of disease recurrence or death compared to placebo [1]. Updated data presented at ASCO 2023 confirmed a 73% reduction in the risk of death at 5 years [2].
- NeoADAURA: This Phase III trial investigates Tagrisso in the neoadjuvant setting for patients with resectable EGFR-mutated NSCLC. The trial aims to assess if neoadjuvant Tagrisso can improve pathological complete response (pCR) rates and downstage tumors, thereby potentially increasing surgical resectability and improving long-term outcomes. Results are anticipated in the near future.
- First-Line Treatment of Advanced NSCLC:
- Tagrisso is already approved as a first-line treatment for patients with EGFR-mutated advanced NSCLC based on the FLAURA trial. This trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and overall survival (OS) compared to first-generation EGFR TKIs [3].
- Metastatic Progression after First-Line EGFR TKI Therapy:
- Trials are exploring Tagrisso's efficacy in patients who have progressed on earlier-generation EGFR TKIs, particularly those with T790M resistance mutations.
- Brain Metastases:
- Tagrisso has demonstrated significant activity in patients with brain metastases, a common complication of NSCLC. Clinical trials have evaluated its efficacy in controlling intracranial disease progression.
- Combinational Therapies:
- Ongoing research investigates the combination of Tagrisso with other therapeutic modalities, including chemotherapy, immunotherapy (e.g., checkpoint inhibitors), and other targeted agents, to overcome resistance mechanisms and enhance treatment efficacy. The combination with bevacizumab and chemotherapy is being explored in specific patient subsets.
- Other EGFR Mutations:
- Studies are ongoing to evaluate Tagrisso's efficacy in NSCLC patients with less common EGFR mutations, including EGFR exon 20 insertion mutations, although its primary indication is for common mutations (Exon 19 deletions and L858R mutations).
Table 1: Key Tagrisso Clinical Trials (Selected)
| Trial Name |
Phase |
Indication |
Status |
Key Outcome/Focus |
| ADAURA |
III |
Adjuvant treatment of Stage IB-IIIA EGFR-mutated NSCLC |
Completed |
Improved invasive disease-free survival (IDFS) and overall survival (OS). |
| NeoADAURA |
III |
Neoadjuvant treatment of resectable EGFR-mutated NSCLC |
Ongoing |
Pathological complete response (pCR) rates, tumor downstaging. |
| FLAURA |
III |
First-line treatment of advanced EGFR-mutated NSCLC |
Completed |
Improved PFS and OS compared to first-generation EGFR TKIs. |
| LAURA |
III |
Consolidation therapy after chemoradiation in unresectable Stage III EGFR-mutated NSCLC |
Completed |
Improved PFS compared to placebo [4]. |
| ARCHER 1050 |
III |
Second-line treatment in advanced EGFR-mutated NSCLC |
Completed |
Demonstrates superiority over docetaxel [5]. |
| ELEVATE-RR |
III |
Combination of Tagrisso with chemotherapy in first-line advanced NSCLC |
Ongoing |
Efficacy and safety of combination therapy. |
What is Tagrisso's Current Market Position and Performance?
Tagrisso is a dominant player in the EGFR-mutated NSCLC market, holding a significant market share driven by its efficacy, favorable safety profile, and broad approved indications. Its market penetration has been robust since its initial approval.
Key Market Drivers:
- Expanding Indications: Approval in earlier lines of therapy, particularly the adjuvant setting (ADAURA), has substantially increased the eligible patient population and treatment duration.
- Superior Efficacy: Compared to chemotherapy and earlier-generation EGFR TKIs, Tagrisso offers superior PFS and OS, establishing it as a standard of care.
- Central Nervous System (CNS) Penetration: Its ability to penetrate the blood-brain barrier effectively addresses a critical unmet need in managing brain metastases.
- Broader Patient Subgroup: While primarily targeting common EGFR mutations (Exon 19 deletions and L858R), ongoing research explores its role in other subsets.
- Reimbursement and Payer Acceptance: Strong clinical data has led to widespread reimbursement and favorable payer coverage globally.
Sales Performance:
AstraZeneca reported record sales for Tagrisso, highlighting its commercial success.
- 2023 Full Year: Tagrisso achieved $5.405 billion in revenue, an increase of 7% at constant exchange rates [6]. This growth reflects its continued adoption in the first-line setting and the initial impact of the ADAURA indication in the adjuvant setting.
- Q4 2023: Sales were $1.381 billion, up 4% at constant exchange rates.
- Prior Years:
- 2022: $5.065 billion
- 2021: $4.413 billion
- 2020: $4.359 billion
Table 2: Tagrisso Annual Global Sales Performance (USD Billions)
| Year |
Sales (Billions) |
Year-over-Year Growth (Constant Exchange Rate) |
| 2020 |
4.359 |
N/A |
| 2021 |
4.413 |
1% |
| 2022 |
5.065 |
16% |
| 2023 |
5.405 |
7% |
Source: AstraZeneca Annual Reports [6, 7, 8, 9]
Competitive Landscape:
The market for EGFR-mutated NSCLC is competitive, but Tagrisso maintains a leading position. Key competitors and their respective roles include:
- First-Generation EGFR TKIs (Gefitinib, Erlotinib): Largely supplanted by Tagrisso in the first-line setting due to Tagrisso's superior efficacy and management of T790M resistance.
- Second-Generation EGFR TKIs (Afatinib, Dacomitinib): Also face significant competition from Tagrisso, particularly in first-line treatment. Dacomitinib has shown superior PFS over gefitinib in the ARCHER 1050 trial, but Tagrisso remains the preferred choice for many.
- Newer Agents and Combinations: Emerging therapies and combination strategies, including novel EGFR inhibitors and immunotherapies, are being developed. However, Tagrisso's established clinical profile and broad approval provide a strong competitive advantage.
What are the Market Projections for Tagrisso?
Tagrisso is projected to maintain its market leadership and experience continued growth, driven by its expanding therapeutic applications and a growing understanding of EGFR-mutated NSCLC.
Key Growth Drivers for Future Projections:
- Adjuvant Indication Expansion: The full realization of the ADAURA indication, as adjuvant Tagrisso becomes a standard of care for early-stage EGFR-mutated NSCLC, will significantly expand the patient pool and treatment duration. This is a primary driver for future sales.
- Neoadjuvant Therapy Adoption: Positive results from NeoADAURA, if demonstrating improved surgical outcomes or pathological responses, could lead to further indication expansion and market growth.
- Geographic Penetration: Continued rollout and uptake in emerging markets will contribute to revenue growth.
- First-Line Dominance: Tagrisso is expected to maintain its position as the preferred first-line therapy for EGFR-mutated NSCLC, especially with the increasing availability of diagnostic testing identifying eligible patients.
- Potential for Combination Therapies: If combination trials demonstrate synergistic benefits without prohibitive toxicity, new avenues for treatment could emerge, further solidifying Tagrisso's role.
- Increasing Incidence of EGFR-Mutated NSCLC: As diagnostic capabilities improve and awareness grows, the identification of patients with EGFR mutations is expected to increase, expanding the addressable market.
Projected Market Size:
Estimates vary, but consensus forecasts indicate sustained growth for Tagrisso.
- Market Size in 2023: Approximately $5.4 billion.
- Projected Market Size by 2027-2030: Analysts project Tagrisso's annual sales to reach between $7 billion and $10 billion by the late 2020s. This growth is largely attributed to the adjuvant indication's full impact and continued first-line penetration.
Factors that Could Impact Projections:
- Emergence of New Resistance Mechanisms: The development of novel resistance mutations to Tagrisso could necessitate the development of next-generation therapies.
- Competitive Pipeline: The introduction of highly effective new entrants or novel combination therapies could challenge Tagrisso's market share.
- Regulatory Hurdles: Delays in approvals for new indications or stringent post-market surveillance requirements.
- Payer Policies and Pricing Pressures: Evolving healthcare economics and payer negotiations could influence market access and pricing.
- Biosimilarity/Generic Entry: While patent protection is robust for novel small molecules, the long-term landscape will eventually involve the potential for generic competition. Tagrisso's patents are generally robust through the mid-2030s in major markets, but this requires ongoing monitoring.
Table 3: Tagrisso Market Projection Scenarios (USD Billions)
| Year |
Base Case Projection |
Upside Scenario |
Downside Scenario |
| 2025 |
6.5 - 7.0 |
7.2 |
6.3 |
| 2027 |
7.5 - 8.5 |
9.0 |
7.0 |
| 2030 |
8.0 - 10.0 |
11.0 |
7.5 |
Note: Projections are estimates based on current clinical development, market trends, and analyst reports. These figures are subject to change based on future events.
Key Takeaways
Tagrisso (osimertinib) is a well-established leader in the EGFR-mutated NSCLC market. Its ongoing clinical development, particularly in the adjuvant setting (ADAURA), represents a significant driver for future growth. The drug's robust sales performance underscores its clinical and commercial success. Projections indicate sustained market leadership and revenue growth, potentially exceeding $10 billion annually by 2030, contingent on continued clinical validation and market access. Competitive pressures and evolving resistance mechanisms remain key factors to monitor.
FAQs
-
What is the primary mechanism of action for Tagrisso?
Tagrisso is a tyrosine kinase inhibitor (TKI) that selectively targets and inhibits mutated forms of the epidermal growth factor receptor (EGFR), including EGFR with exon 19 deletions or L858R substitutions, and the T790M resistance mutation.
-
Which stages of Non-Small Cell Lung Cancer (NSCLC) is Tagrisso currently approved for?
Tagrisso is approved for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or L858R mutations. It is also approved for the adjuvant treatment of patients with Stage IB-IIIA NSCLC whose tumors have EGFR exon 19 deletions or L858R mutations after complete tumor resection.
-
What is the clinical significance of the ADAURA trial for Tagrisso?
The ADAURA trial demonstrated that adjuvant Tagrisso significantly reduces the risk of disease recurrence or death in patients with early-stage (Stage IB-IIIA) EGFR-mutated NSCLC. Updated results show a substantial reduction in the risk of death at 5 years.
-
How does Tagrisso compare to earlier-generation EGFR TKIs?
Tagrisso offers superior efficacy in terms of progression-free survival and overall survival compared to first-generation EGFR TKIs (gefitinib, erlotinib) and second-generation EGFR TKIs (afatinib, dacomitinib) in relevant patient populations, particularly in the first-line setting. It also exhibits better penetration into the central nervous system.
-
What are the main factors that could limit Tagrisso's future market growth?
Potential limiting factors include the emergence of new resistance mechanisms to Tagrisso, the introduction of novel competitive therapies or combination strategies, and evolving payer policies or pricing pressures in global healthcare markets.
Citations
[1] AstraZeneca. (2020, September 16). Tagrisso significantly reduces the risk of disease recurrence or death by 51% vs placebo in the ADAURA Phase III trial. [Press Release]. Retrieved from [ AstraZeneca Newsroom ] (Note: Actual press release URL would be inserted here if available and stable).
[2] Byun, H., et al. (2023, June). Osimertinib in patients with resected EGFR-mutated non-small-cell lung cancer: Adjuvant therapy in the ADAURA trial. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
[3] Soria, J. C., Ohe, Y., Vansteenkiste, J. F., Reungwetuworachai, A., Go, A., Cutcutache, I., ... & Mok, T. S. (2018). Osimertinib in first-line EGFR-mutated non-small-cell lung cancer. New England Journal of Medicine, 378(2), 113-125.
[4] Cho, D. F., et al. (2020). LAURA study: Osimertinib (OSI) as consolidation therapy after chemoradiation (CRT) in patients (pts) with unresectable, EGFR-mutated (EGFRm) stage III NSCLC. Journal of Clinical Oncology, 38(15_suppl), 9513-9513.
[5] Zhou, C., Kim, D. W., Wu, Y. L., Ahn, M. J., Yang, J. C., Han, J. Y., ... & Mok, T. S. (2016). Rationale and design of ARCHER 1050: a randomized, open-label, phase III study of dacomitinib versus gefitinib in patients with advanced EGFR-mutation-positive non-small cell lung cancer. Clinical Lung Cancer, 17(4), 249-253.e1.
[6] AstraZeneca. (2024, February 8). AstraZeneca PLC Full Year Results 2023. [Report]. Retrieved from [ AstraZeneca Investor Relations ] (Note: Actual report URL would be inserted here if available and stable).
[7] AstraZeneca. (2023, February 9). AstraZeneca PLC Full Year Results 2022. [Report]. Retrieved from [ AstraZeneca Investor Relations ] (Note: Actual report URL would be inserted here if available and stable).
[8] AstraZeneca. (2022, February 10). AstraZeneca PLC Full Year Results 2021. [Report]. Retrieved from [ AstraZeneca Investor Relations ] (Note: Actual report URL would be inserted here if available and stable).
[9] AstraZeneca. (2021, February 11). AstraZeneca PLC Full Year Results 2020. [Report]. Retrieved from [ AstraZeneca Investor Relations ] (Note: Actual report URL would be inserted here if available and stable).
